Results 191 to 200 of about 36,830 (259)

Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)

JEADV Clinical Practice, Volume 5, Issue 2, Page 517-528, June 2026.
ABSTRACT Background Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available.
Emily Goddard, Aaron Keal, James Hetherington, Sophie Barlow, David Wu, Melany Worbes‐Cerezo, Alexander Litvintchouk   +6 more
wiley   +1 more source

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, Volume 5, Issue 2, Page 651-655, June 2026.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Serum and Fecal Calprotectin Levels Do Not Alter Significantly in Patients With Psoriasis Switching to Brodalumab After Loss of Effect From TNF‐α Inhibitors

JEADV Clinical Practice, Volume 5, Issue 2, Page 615-619, June 2026.
ABSTRACT Background Psoriasis is a chronic inflammatory skin disease often associated with systemic conditions like psoriatic arthritis and inflammatory bowel disease (IBD). Calprotectin, an inflammatory biomarker commonly used in IBD, has also been found elevated in psoriasis.
Admir Vižlin, Hans‐Peter Claesson, Ylva Andersch Björkman, Martin Gillstedt, Eva Klingberg, Emanuela Micu, Amra Osmančević   +6 more
wiley   +1 more source

Role of the S1P/S1PR axis in inflammation and structural damage in psoriatic arthritis: a cross-sectional study with clinical, biochemical and imaging correlation. [PDF]

RMD Open
Ruiz-Montesinos D, Mendoza-Mendoza D, Bocio Núñez J, Dominguez-Quesada C, Serrano-Guijo ML, Vázquez-Gámez MÁ, Rico MÁ, Colmenero MÁ, Perez-Venegas JJ, Montoya-García MJ, Giner M.   +10 more
europepmc   +1 more source

Successful Use of Bimekizumab in Refractory Acute Generalised Exanthematous Pustulosis Triggered by Amoxicillin‐Clavulanate

JEADV Clinical Practice, Volume 5, Issue 2, Page 669-672, June 2026.
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge, Charlotte Vogel, Theresa Hempel, Basil Signer, Nikhil Yawalkar, Kristine Heidemeyer   +5 more
wiley   +1 more source

Comment on "The Brazilian Portuguese version of the psoriasis epidemiology screening tool (PEST-bp) is reliable and accurate: a cross-sectional study from southern Brazil". [PDF]

An Bras Dermatol
Mahida K, Jagtap SR.
europepmc   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Approach to Nail Pitting in Pediatric and Adolescent Patients: A Dermatology Perspective

JEADV Clinical Practice, Volume 5, Issue 2, Page 394-401, June 2026.
ABSTRACT This narrative review aims to discuss the etiologies of nail pitting in pediatric and adolescent patients, while providing a framework for further evaluation of possible underlying systemic conditions and their clinical findings from a dermatologic standpoint.
Elizabeth Botto, Victoria Griffith, Samuel Stahly, Jere Mammino   +3 more
wiley   +1 more source

Development of Arthritis in a Large Real-World Cohort of Patients With Pediatric Onset Psoriasis. [PDF]

J Psoriasis Psoriatic Arthritis
Al-Gawahiri M, de Jong EMGJ, Schatorjé EJH, Hoppenreijs EPAH, van den Reek JMPA, Seyger MMB.   +5 more
europepmc   +1 more source

Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis.
Jarno Rutanen, Pekka Heino, Kati Sarnola, Terhi Kurko   +3 more
wiley   +1 more source